Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients. - Wikidata - awgldk - TriplyDB

Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients.

Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients.

http://www.wikidata.org/entity/Q46406579

about

Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon Warfarin Pharmacogenetics: New Life for an Old Drug Exploring the distribution of genetic markers of pharmacogenomics relevance in Brazilian and Mexican populations VKORC1 haplotypes in five East-Asian populations and Indians.Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing Pharmacogenetics of warfarin: challenges and opportunities.CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies.CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement Pharmacogenetics in Jewish populations.A review of a priori regression models for warfarin maintenance dose prediction.Pharmacogenetics in the brazilian population.Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry.Population diversity and the performance of warfarin dosing algorithms.Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU Pharmacogenomics, human genetic diversity and the incorporation and rejection of color/race in Brazil.Genome-wide association study of warfarin maintenance dose in a Brazilian sample The Emerging Role of Admixture in the Pharmacogenetics of Puerto Rican Hispanics.Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients Pharmacogenomics of warfarin in populations of African descent.Personalized medicine and the clinical laboratory.Exposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosing A systems approach to designing effective clinical trials using simulations.Warfarin pharmacogenetics: How close are we to clinical practice?Inter and intra ethnic variation of vitamin K epoxide reductase complex and cytochrome P450 4F2 genetic polymorphisms and their prevalence in South Indian population.Clinical pharmacogenomics of warfarin and clopidogrel.Pharmacogenomic implications of population admixture: Brazil as a model case.Pharmacogenetics of coumarin anticoagulants in Brazilians.Warfarin Pharmacogenomics in Diverse Populations.Influence of APOE Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement: A Systematic Review and Meta-Analysis.Warfarin Dosing Algorithms Underpredict Dose Requirements in Patients Requiring ≥7 mg Daily: A Systematic Review and Meta-analysis.Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements.Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration.Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study.Influence of ORM1 polymorphisms on the maintenance stable warfarin dosage.VKORC1 polymorphisms in Brazilians: comparison with the Portuguese and Portuguese-speaking Africans and pharmacogenetic implications.Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese.Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort.Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.

P2860

Q24289220-AF28F5B8-A079-4BAF-A09B-61AC3CAAF199 Q27002899-FC4F0976-3470-4DC8-8E10-139F47F0C826 Q27006860-DF3BDEC2-73F6-4A1E-AD6E-D1AAF29E4B0A Q28468726-FB457185-4ACE-45E8-8AE7-1E0D2ED127B9 Q28545128-7A20A853-4BB8-4B8F-91ED-52B5B6385513 Q33511512-B4C28BC3-AAAC-4781-9BC1-FEC74920A1FC Q33813830-8BC8E919-1A66-4A0B-8AF7-4645002BB5DC Q33819050-BBD5992D-31B2-4F30-83FC-9172EF5D71E2 Q33990359-B49AC2D9-6622-4EEF-A605-7C912FF272F2 Q34026257-A5706AD2-E7C0-4194-A2FC-4E0586D7FF61 Q34458720-2836203D-40C1-40CD-A47F-4EF5D30AE56D Q34690708-251628AE-F072-4C55-95DE-0A535D6E6129 Q35155213-53C6F966-23F6-4FB8-9709-880F94DA860F Q35219654-EEF65762-908C-4646-B590-FAC4C59F1E3C Q35219658-6F7D9EE6-F4B1-4C2F-B0F9-F9B5971827BC Q35795982-2EA967EC-5AB8-43FB-86F8-69CAECD8465A Q35961759-0AC10F38-0416-4065-9EB7-085A8D9C50D0 Q36068687-85BCC2F1-4C32-4D83-95CD-0033E4F01F17 Q36447492-A9AB5B12-169D-4761-A939-2AE2EE6CA2A8 Q36511894-F8138959-2717-4F08-B934-DD629DDAE913 Q36629209-6ADB7CC8-F55B-43B2-884C-A0E9BFA6C3D1 Q36916966-43CA81B0-AA90-460C-AA4E-14F380762A39 Q36921008-8980F79D-E42B-4E4A-8CF8-7C9FDF07EBA9 Q37106741-4AA0E83F-76BB-40FC-880A-A94B5B5752C5 Q37345374-DF75BBAF-698F-445E-97E8-8BC7E7D44505 Q37345384-8FF01795-9D0D-4662-B0EC-87FE0E15EAAE Q38016848-ED03557A-6D91-4161-B660-AC2C563507B4 Q38180220-DF81B4BC-35A5-42D9-844F-016FBBD36754 Q38262829-4FB0468F-2912-4987-950C-5527FC8AD9A1 Q38696567-EC7045F7-8623-4868-A854-CAF982D66938 Q38803472-EB0375D3-96F9-4257-8C57-E04F03834B14 Q38979667-4649D95E-754F-4719-A7A8-C012A42A6D70 Q39862947-2E8E2CD6-CD85-4AAD-9D3F-0B3C2B0F8347 Q40862073-43510F2D-91B9-4BB8-A60F-D9457EB057C1 Q42703883-06ACC543-8B54-4A1D-9735-2B79C4E401B8 Q42713959-66EBCFA7-51F6-482B-8C16-1DE7370CA3A5 Q42879834-14044C21-49BE-4150-8424-B3DEC3A7B0DB Q42910090-6A8B893E-23B2-48F3-A3D1-3C16BDD3B5A4 Q43150810-88F0FCC0-9F73-45AC-AE02-9825C9B756E9 Q43258272-82352933-3CDB-4B40-8FC7-5CD3D1F929CE

P2860

Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients.

http://www.wikidata.org/entity/Q46406579

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients.

@en

Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients.

@nl

type

label

Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients.

@en

Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients.

@nl

prefLabel

Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients.

@en

Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients.

@nl

P1433

Q46406579-6FB12504-DCC6-40E9-B792-3712381F6CD3

P1476

Q46406579-187AAF5D-5E92-47ED-A033-EA7838D35231

P2093

Q46406579-249D2AA1-4527-4FF8-A3C5-8A25BCE2A726

Q46406579-4CA5C37C-F1C2-479E-8DF3-EB861341CE98

Q46406579-7D26074C-2909-41FF-AA30-1BD94600A34D

Q46406579-8D9DED8F-376F-4FC7-8E86-93D135847B68

Q46406579-9CAB9EE2-B803-4B33-B939-03074C8E22AC

Q46406579-A0510347-4C33-40AC-88B7-2576F5B20AA4

P2860

Q46406579-01570385-DEA2-4CBB-B145-0C9EF2A0678C

Q46406579-0204F44A-22C6-4CA7-864B-187FD759F265

Q46406579-0C5C86AB-BBE1-4C7B-80A1-E2B6DF43AE69

Q46406579-128E68C4-C9EA-4E42-902D-F743B20D1820

Q46406579-12D9014C-564A-4F62-B90B-8531ABCF0DE7

Q46406579-1D0D28A6-7197-48DA-8416-EF7BF3293E2C

Q46406579-201B0BB3-605C-49FB-A64B-5005625E6AAA

Q46406579-2A58CEF9-92BC-4B1B-B050-B4C6FDD02DF7

Q46406579-2B092CE7-256F-4F24-99E3-EFAF5C49F60F

Q46406579-2E5189FC-584C-4570-B9D5-9E85901A3359

P2888

Q46406579-4AEDBF3A-68C1-4CCD-867F-5BFCA717FE5A

P304

Q46406579-9CAA7805-E368-4BC6-8CF6-B10BCDFE993A

P31

Q46406579-83FCEC6B-C998-424D-8462-B967C81977C4

P356

Q46406579-2EAABC7B-E96A-41B1-912E-B1AA45B66F3B

P407

Q46406579-39C07977-C7BD-47BC-961C-382200CF2882

P433

Q46406579-C86C8705-09CE-4917-A8EF-309C9E9BD05D

P478

Q46406579-813A664A-BFCE-4E1D-862E-8FC4C95675AE

P50

Q46406579-0C8DCE80-3AD0-4F97-9C3E-4372E5717692

Q46406579-74120092-667D-43C6-931E-4888B4D641EC

P577

Q46406579-B6BD4C30-61EC-4F22-872C-68B533CA9C06

P5875

Q46406579-898C95D1-FC6F-4720-944B-366999E1A7AC

P6179

Q46406579-B67C1943-DFE8-46BA-AC4E-5AB3DFBFAE11

P698

Q46406579-1CF20977-8E55-4994-B10D-859FEBCCB642

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients.

@en

P2093

C J Struchiner

http://www.w3.org/2001/XMLSchema#string

E B Ojopi

http://www.w3.org/2001/XMLSchema#string

E Silva-Assunção

http://www.w3.org/2001/XMLSchema#string

F Rangel

http://www.w3.org/2001/XMLSchema#string

I S C Santana

http://www.w3.org/2001/XMLSchema#string

J A Perini

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

Identification of the gene for vitamin K epoxide reductase

Score tests for association between traits and haplotypes when linkage phase is ambiguous

Hemorrhagic complications of anticoagulant treatment.

Common VKORC1 and GGCX polymorphisms associated with warfarin dose.

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

CYP4F2 genetic variant alters required warfarin dose

Genetic determinants of response to warfarin during initial anticoagulation

Evaluation of genetic factors for warfarin dose prediction

P2888

P304

722-728

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CLPT.2008.166

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

84

http://www.w3.org/2001/XMLSchema#string

P50

Guilherme Suarez-Kurtz

Emmanuel Dias-Neto

P577

2008-08-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23220424

http://www.w3.org/2001/XMLSchema#string

P6179

1040035270

http://www.w3.org/2001/XMLSchema#string

P698

18754001

http://www.w3.org/2001/XMLSchema#string